AG1 Sells the Most. AI Picks Thorne. Four Science-Led Brands Captured an Estimated 47% of Citation Share Across 3,800 Tested Prompts.

5W’s Supplements AI Visibility Index 2026 measured citation share across 3,800 prompts (Jan–Apr 2026) on major AI engines and found Thorne, Seed, AG1, and Momentous accounted for an estimated >47% of observed citations, with AG1 ranking third behind Thorne and Seed. The report highlights that AI citation rank diverges from revenue rank more in supplements than in other 5W-measured sectors, attributing visibility to “trust signals” (NSF/USP/Informed Sport certifications, peer-reviewed citation depth, and per-batch COAs) and “podcast halo” effects (~3.4x higher citation rates for brands with sustained science-longevity podcast presence). Overall impact appears informational for brand strategy rather than a direct macro or earnings catalyst.

Analysis

This is less a supplement industry read-through than a signal about who controls discovery in an AI-mediated marketplace. For public equities, the only clean listed proxy is GOOGL: if AI answers become the default top-of-funnel for high-intent health queries, Google’s distribution becomes more valuable, but only if it can convert trust into monetized sessions rather than answer leakage. The immediate market impact is likely small; the larger effect is a slower re-rating of brands that can turn credibility into lower CAC and defend premium pricing.

The second-order winner set is narrow-brand, high-trust DTC operators; the loser set is broad catalogs and private-label-heavy sellers whose semantic footprint is diluted. Over 1-3 months, expect incremental spend to shift toward podcasts, clinical content, and certification signaling because those inputs appear to compress the AI answer set. That helps agencies, media owners, and certification ecosystems more than it helps the underlying supplement shelves.

The contrarian point is that citation share is not demand share, and model rankings are fragile to product changes. A single reweighting of source selection or an update to Google AI Overviews could invert these rankings quickly, so this is a weak standalone equity signal unless it shows up in conversion data. The thesis breaks if AI answers stop privileging editorial/podcast authority or if Google’s AI layer reduces, rather than expands, commercial query monetization.

Key Decisions for Investors

• No trade in ARBU or GAP; the article has no credible fundamental transmission to either name, so avoid manufacturing a catalyst.
• Keep GOOGL on a 1-3 month watchlist as a modest long vs QQQ only if upcoming Search/AI product disclosures show AI Overviews improving query retention or monetization; otherwise stay flat.
• Set an alert on Google’s next earnings call for any commentary on AI answer-layer ad yield and traffic mix; if AI features are clearly cannibalizing monetized clicks, fade the long thesis.
• Do not short supplement brands here: the cited ranking is a marketing/discovery signal, not an audited revenue bridge, so the risk/reward on a public short is poor without comp data.
• If we gain liquid public exposure to consumer-health or e-commerce names later, revisit a pair trade favoring high-trust niche brands over broad catalogs; today the signal is too indirect for size.